Literature DB >> 28493512

Decreased expression of hsa_circ_0003570 in hepatocellular carcinoma and its clinical significance.

Liyun Fu1,2, Shengdong Wu3, Ting Yao1, Qingqing Chen1, Yi Xie1, Sheng Ying2, Zhigang Chen2, Bingxiu Xiao1, Yaoren Hu2.   

Abstract

BACKGROUND: Circular RNAs (circRNAs) constitute a class of non-coding RNAs recently discovered to be widespread and abundant in mammalian cells. However, the expression features of most of circRNAs in hepatocellular carcinoma (HCC) are unraveled. In this study, we focused on hsa_circ_0003570, which was found to be down-regulated in HCC tissues in our previous microarray screening.
METHODS: The hsa_circ_0003570 levels in HCC cell lines, HepG2, SMMC-7721, MHCC97L, MHCC97H, and HCCLM3, and human normal hepatic cell line L02 were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Then, its levels in 107 paired HCC tissues and adjacent non-tumor tissues, 60 liver biopsy samples from patients with chronic liver diseases were detected by qRT-PCR. The receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of hsa_circ_0003570 for HCC.
RESULTS: Hsa_circ_0003570 was not only first found down-regulated in HCC cell lines (P<.001) but also in HCC tissues (P<.001). Moreover, hsa_circ_0003570 was gradually decreased from chronic hepatitis (CH), to liver cirrhosis (LC) and to HCC tissues (P<.01). Its expression levels were significantly correlated with tumor diameter (P=.035), differentiation (P=.013), microvascular invasion (P=.045), Barcelona Clinic Liver Cancer stages (P=.011), tumor-node-metastasis stages (P=.016), and serum alpha-fetoprotein levels (P=.031). The ROC curve demonstrated that hsa_circ_0003570 had poor performance for differentiating HCC from LC and CH, but had relatively good performance for differentiating LC from CH.
CONCLUSIONS: These results indicated that hsa_circ_0003570 expression levels were associated with HCC clinicopathological characteristics.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic hepatitis; circular RNA; cirrhosis; hepatocellular carcinoma; hsa_circ_0003570

Mesh:

Substances:

Year:  2017        PMID: 28493512      PMCID: PMC6816847          DOI: 10.1002/jcla.22239

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  35 in total

1.  An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

Authors:  P Bedossa; T Poynard
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma pathogenesis: from genes to environment.

Authors:  Paraskevi A Farazi; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

3.  Contributions of lung tissue extracts to invasion and migration of human hepatocellular carcinoma cells with various metastatic potentials.

Authors:  Xue-Ning Ji; Sheng-Long Ye; Yan Li; Bo Tian; Jie Chen; Dong-Mei Gao; Jun Chen; Wei-Hua Bao; Yin-Kun Liu; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-26       Impact factor: 4.553

Review 4.  Circular RNA and miR-7 in cancer.

Authors:  Thomas B Hansen; Jørgen Kjems; Christian K Damgaard
Journal:  Cancer Res       Date:  2013-09-06       Impact factor: 12.701

5.  Recent trend of clinical features in patients with hepatocellular carcinoma.

Authors:  Yuko Nagaoki; Hideyuki Hyogo; Hiroshi Aikata; Mio Tanaka; Noriaki Naeshiro; Takashi Nakahara; Yoji Honda; Daisuke Miyaki; Tomokazu Kawaoka; Shintaro Takaki; Akira Hiramatsu; Koji Waki; Michio Imamura; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2011-12-13       Impact factor: 4.288

6.  Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma.

Authors:  Meilin Qin; Gang Liu; Xisong Huo; Xuemei Tao; Xiaomeng Sun; Zhouhong Ge; Juan Yang; Jia Fan; Lei Liu; Wenxin Qin
Journal:  Cancer Biomark       Date:  2016       Impact factor: 4.388

7.  ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.

Authors:  Zhicheng Yao; Jingyan Luo; Kunpeng Hu; Jizong Lin; He Huang; Qiangliang Wang; Peng Zhang; Zhiyong Xiong; Chonghua He; Zejian Huang; Bo Liu; Yang Yang
Journal:  Mol Oncol       Date:  2017-03-17       Impact factor: 6.603

8.  Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.

Authors:  Yulong Zheng; Lihua Jiang; Yongxian Hu; Cheng Xiao; Nong Xu; Jianying Zhou; Xinhui Zhou
Journal:  BMC Cancer       Date:  2017-02-28       Impact factor: 4.430

9.  Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.

Authors:  Tianhui Liu; Mingjie Yao; Shuhong Liu; Lu Wang; Leijie Wang; Jinlin Hou; Xiong Ma; Jidong Jia; Jingmin Zhao; Hui Zhuang; Fengmin Lu
Journal:  Oncotarget       Date:  2017-03-07

10.  The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells.

Authors:  Huanyu Xu; Sen Guo; Wei Li; Ping Yu
Journal:  Sci Rep       Date:  2015-07-27       Impact factor: 4.379

View more
  34 in total

1.  Circular RNA 0068669 as a new biomarker for hepatocellular carcinoma metastasis.

Authors:  Ting Yao; Qingqing Chen; Zhouwei Shao; Zhihua Song; Liyun Fu; Bingxiu Xiao
Journal:  J Clin Lab Anal       Date:  2018-05-21       Impact factor: 2.352

2.  Circular RNA as a biomarker for cancer: A systematic meta-analysis.

Authors:  Yulong Li; Xiaoli Zeng; Jianxun He; Yuan Gui; Song Zhao; Hua Chen; Qi Sun; Nan Jia; Hui Yuan
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

3.  CCRDB: a cancer circRNAs-related database and its application in hepatocellular carcinoma-related circRNAs.

Authors:  Qingyu Liu; Yanning Cai; Haiquan Xiong; Yiyun Deng; Xianhua Dai
Journal:  Database (Oxford)       Date:  2019-01-01       Impact factor: 3.451

Review 4.  Encoding activities of non-coding RNAs.

Authors:  Yanan Pang; Chuanbin Mao; Shanrong Liu
Journal:  Theranostics       Date:  2018-03-28       Impact factor: 11.556

5.  CircRNAs as biomarkers of cancer: a meta-analysis.

Authors:  Miao Wang; Yuxi Yang; Jian Xu; Wen Bai; Xueli Ren; Huijian Wu
Journal:  BMC Cancer       Date:  2018-03-20       Impact factor: 4.430

6.  Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis.

Authors:  Honglei Wang; Yi Xiao; Li Wu; Dachang Ma
Journal:  Int J Oncol       Date:  2018-02-05       Impact factor: 5.650

7.  Identification and analysis of circRNA-miRNA-mRNA regulatory network in hepatocellular carcinoma.

Authors:  Daxiang Zhou; Ling Dong; Lishan Yang; Qiang Ma; Feng Liu; Yanjie Li; Shu Xiong
Journal:  IET Syst Biol       Date:  2020-12       Impact factor: 1.615

8.  Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.

Authors:  Yujuan Lu; Jingzhi Zhang; Yanhui Wu
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

Review 9.  Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma.

Authors:  Rui Liao; Lei Liu; Jian Zhou; Xufu Wei; Ping Huang
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

Review 10.  Circular RNAs in cancer: opportunities and challenges in the field.

Authors:  L S Kristensen; T B Hansen; M T Venø; J Kjems
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.